Credit: EASL via Linkedin
June 7, 2024 11:21 AM EDT
R&D

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

Katherine Lewin

News Reporter

Max Bayer

Pharma Reporter

At this year’s EASL In­ter­na­tion­al Liv­er Con­gress, Vir took cen­ter stage Wednes­day to re­port ear­ly Phase 2 da­ta for its he­pati­tis D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times